A recent drug test involving a former undersecretary has sparked debate regarding the handling of counter-samples in drug screenings for authorities. The controversy prompted a review of existing legislation, internal guidelines from the Comptroller General’s Office, SENDA’s (National Service for the Prevention and Rehabilitation of Drug Use) tender specifications, and proposed executive reforms. This investigation aims to clarify what aspects of counter-sample procedures are currently regulated and where gaps in the regulations exist. The focus is on understanding the rules surrounding secondary testing and ensuring transparency in the process when high-ranking officials are subject to drug tests. The review seeks to address potential ambiguities and establish clearer protocols for handling counter-samples. Ultimately, the goal is to determine if current procedures are adequate and legally sound following this high-profile case.